Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 8/20 | 0.38 |
| ▸ | KDR | P35968 | 7/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SIK1 | P57059 | 1/20 | 0.36 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.36 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648039 | 0.91 | KDR (0.40) | HPGDKDRATMALDH1A1NTRK1 | |
| SCHEMBL2649465 | 0.89 | HPGD (0.39) | HPGDKDRATMALDH1A1NTRK1 | |
| SCHEMBL2940257 | 0.87 | GPR119 (0.45) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL6856564 | 0.84 | ATM (0.38) | HPGDKDRATMALDH1A1NPC1 | |
| SCHEMBL5782547 | 0.83 | FGFR1 (0.53) | RIPK1RIPK3HPGDALDH1A1NPC1 | |
| SCHEMBL2648823 | 0.82 | KDR (0.44) | KDRALDH1A1 | |
| SCHEMBL2652084 | 0.81 | ALDH1A1 (0.44) | HPGDKDRALDH1A1NPC1GLA | |
| SCHEMBL2647976 | 0.80 | HPGD (0.42) | HPGDKDRALDH1A1NPC1GLA | |
| SCHEMBL2650751 | 0.80 | CYP1A2 (0.49) | HPGDKDRALDH1A1 | |
| SCHEMBL5782463 | 0.80 | RIPK1 (0.46) | RIPK1RIPK3HPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | claimed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | claimed |
| JP-2003502405-A | — | — | 2003-01-21 | — | — | JP | claimed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | claimed |
| EP-1194410-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2006-01-18 | — | — | EP | disclosed |
| US-6936613-B2 | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | RIPK1 3082/4885RIPK3 2320/4885HPGD 1452/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | RIPK1 3059/4885RIPK3 2226/4885HPGD 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.